Dabigatran etexilate (Pradaxa®) was recently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). As the first new oral anticoagulant in over 50 years, dabigatran provides an alternative to warfarin with predictable pharmacokineti